PART1 and ovarian cancer: Several lncRNAs have been reported to promote the cisplatin resistance in ovarian cancer, including ACTA2-AS1, CCAT1, CRNDE, HOTAIR, HOXA11-AS, TCF7, PANDAR, PART1, MALAT1, UCA1, WDFY3-AS2.